Compare Incyte Corporation (INCY) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Omnicom Group Inc. — how do they compare? Incyte Corporation trades at $120.93 (market cap $24.54B), while Omnicom Group Inc. trades at $85.32 (market cap $23.58B). The key difference: Incyte Corporation and Omnicom Group Inc. are close in size by market cap, and Omnicom Group Inc. pays a 3.72% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | OMC | |
|---|---|---|
Market Cap | $24.54B | $23.58B |
Sector | Health | Media |
52-Week High | $129.93 | $86.22 |
52-Week Low | $81.61 | $67.27 |
Enterprise Value | $20.04B | $31.66B |
Dividend Yield | — | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Omnicom Group (OMC) trades at $85.34, up 0.82% today, with a bullish technical signal from moving averages and a consensus price target of $107.00. Recent Q2 2026 earnings beat expectations with $2.65 EPS and 6.1% organic revenue growth, though net income margin remains thin at 1.74%. The company shows strong cash flow from operations at $2.94 billion in 2025 and pays a $0.80 quarterly dividend.
Outlook is positive with post-merger synergies driving margin expansion, but high P/E of 232.3 and integration risks from the Interpublic acquisition pose challenges. Analyst sentiment is mixed with 32% buy ratings, highlighting value potential amid execution concerns. Key catalysts include sustained organic growth and cost savings realization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
